Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $310,250.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Free Report) Director Cyrus Harmon sold 25,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $12.41, for a total value of $310,250.00. Following the completion of the transaction, the director now owns 846,283 shares in the company, valued at $10,502,372.03. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Cyrus Harmon also recently made the following trade(s):

  • On Wednesday, January 31st, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total transaction of $305,750.00.

Olema Pharmaceuticals Trading Down 5.0 %

OLMA opened at $13.83 on Wednesday. Olema Pharmaceuticals, Inc. has a 12 month low of $3.00 and a 12 month high of $17.79. The company has a market cap of $762.03 million, a PE ratio of -5.96 and a beta of 2.13. The company has a 50 day moving average of $13.34 and a 200 day moving average of $12.96.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on OLMA shares. Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Citigroup initiated coverage on shares of Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $21.00.

Read Our Latest Stock Report on OLMA

Hedge Funds Weigh In On Olema Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $7,574,000. Virtus ETF Advisers LLC purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $105,000. Legal & General Group Plc boosted its stake in shares of Olema Pharmaceuticals by 910.8% in the 4th quarter. Legal & General Group Plc now owns 24,533 shares of the company’s stock valued at $344,000 after purchasing an additional 22,106 shares in the last quarter. Barclays PLC raised its position in Olema Pharmaceuticals by 831.8% in the 4th quarter. Barclays PLC now owns 43,396 shares of the company’s stock worth $609,000 after purchasing an additional 38,739 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Olema Pharmaceuticals by 58.2% in the fourth quarter. Vanguard Group Inc. now owns 2,705,895 shares of the company’s stock worth $37,964,000 after purchasing an additional 995,588 shares during the last quarter. 88.00% of the stock is owned by institutional investors.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.

See Also

Insider Buying and Selling by Quarter for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.